Evommune (EVMN) Prepaid Assets (2024 - 2026)

Evommune (EVMN) reported Prepaid Assets of $4.4 million for Q1 2026, up 2.64% quarter-over-quarter from $4.3 million in Q4 2025.

Evommune (EVMN) Prepaid Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Prepaid Assets data on file, last reported at $4.4 million in Q1 2026.

  • Prepaid Assets for Q1 2026 came in at $4.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (changed N/A YoY), and the FY2025 annual result was $4.3 million, up 119.61% from the prior year.
  • Prepaid Assets grew to $4.4 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $5.9 million in Q3 2025 and troughed at $1.9 million in Q4 2024.
  • A 3-year average of $4.1 million and a median of $4.3 million in 2025 frame the typical range for Prepaid Assets.
  • On a YoY basis, Prepaid Assets climbed as much as 119.61% in 2025 and fell as far as 119.61% in 2025.
  • A 3-year view of Prepaid Assets shows it stood at $1.9 million in 2024, then jumped by 119.61% to $4.3 million in 2025, then advanced by 2.64% to $4.4 million in 2026.
  • Business Quant data shows EVMN's Prepaid Assets at $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $5.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Evommune 695.29 Mn 483.82 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 4.39 Mn
Dec 31, 2025 4.28 Mn
Sep 30, 2025 5.88 Mn
Dec 31, 2024 1.95 Mn